Browsing Tag
PCSK9
4 posts
The oral biologics revolution: How macrocyclic peptides could reshape drug delivery
Macrocyclic peptides are revolutionizing oral biologics. Explore how Merck, Protagonist, and others are turning injectables into convenient, high-impact pills.
June 12, 2025
Can Merck rebuild its cardiovascular empire post-Keytruda? A closer look at its next decade of drug growth
With Keytruda’s patent expiry nearing, Merck is betting on enlicitide and sotatercept to build a new cardiovascular empire. Can it succeed?
June 10, 2025
Merck’s enlicitide shows major LDL-C reduction in Phase 3 trials, raising hopes for first oral PCSK9 approval
Merck’s enlicitide hits key milestones in Phase 3 trials, bringing the first oral PCSK9 inhibitor closer to market. Will this reshape LDL-C treatment?
June 9, 2025
Scribe Therapeutics unveils ELXR technology breakthrough at Keystone Symposia 2025
Scribe Therapeutics has presented new data on its Epigenetic Long-Term X-Repressor (ELXR) technology at the 2025 Keystone Symposia…
March 7, 2025